| 000 | 01584 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517231216.0 | ||
| 264 | 0 | _c20190812 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1462-0332 | ||
| 024 | 7 |
_a10.1093/rheumatology/key213 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSircar, Geetabali | |
| 245 | 0 | 0 |
_aIntravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. _h[electronic resource] |
| 260 |
_bRheumatology (Oxford, England) _c12 2018 |
||
| 300 |
_a2106-2113 p. _bdigital |
||
| 500 | _aPublication Type: Equivalence Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung _xpathology |
| 650 | 0 | 4 |
_aLung Diseases, Interstitial _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aRituximab _xtherapeutic use |
| 650 | 0 | 4 |
_aScleroderma, Diffuse _xcomplications |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 |
_aSkin _xpathology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVital Capacity _xdrug effects |
| 650 | 0 | 4 | _aWalk Test |
| 700 | 1 | _aGoswami, Rudra Prosad | |
| 700 | 1 | _aSircar, Dipankar | |
| 700 | 1 | _aGhosh, Alakendu | |
| 700 | 1 | _aGhosh, Parasar | |
| 773 | 0 |
_tRheumatology (Oxford, England) _gvol. 57 _gno. 12 _gp. 2106-2113 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/key213 _zAvailable from publisher's website |
| 999 |
_c28676517 _d28676517 |
||